Osteopenia

New England Journal of Medicine

Volumn 356, Issue 22, 2007, Pages 2293-2300

  Khosla, Sundeep ^a   Melton III, L Joseph ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; IBANDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

ANAMNESIS; ARTICLE; BODY MASS; BODY WEIGHT; BONE DENSITY; BONE NECROSIS; BONE TURNOVER; BREAST CANCER; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRINKING BEHAVIOR; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOMETRIUM HYPERPLASIA; ESOPHAGITIS; FEMUR NECK; HEART INFARCTION; HEIGHT; HOT FLUSH; HUMAN; LEG CRAMP; LIFESTYLE MODIFICATION; NAUSEA; OSTEOPENIA; POSTMENOPAUSE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SCORING SYSTEM; SPINE; STROKE; VERTEBRA FRACTURE; EXERCISE; FEMALE; FRACTURE; METABOLIC BONE DISEASE; MIDDLE AGED; PRACTICE GUIDELINE; REFERENCE VALUE; REVIEW; RISK FACTOR; RISK REDUCTION;

BONE DENSITY; BONE DISEASES, METABOLIC; CALCIUM; DIPHOSPHONATES; EXERCISE; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; PRACTICE GUIDELINES; REFERENCE VALUES; RISK FACTORS; RISK REDUCTION BEHAVIOR; VITAMIN D;

EID: 34249825222     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp070341     Document Type: Article

References (52)

1. Cooper A. A treatise on dislocations and fractures of the joints. London: Churchill, 1842.
2. Lochmuller EM, Burklein D, Kuhn V, et al. Mechanical strength of the thoracolumbar spine in the elderly: prediction from in situ dual-energy X-ray absorptiometry, quantitative computed tomography (QCT), upper and lower limb peripheral QCT, and quantitative ultrasound. Bone 2002;31:77-84.
3. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.
4. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: World Health Organization, 1994.
5. The frequency of bone disease. In: Bone health and osteoporosis: a report of the Surgeon General. Rockville, MD: Department of Health and Human Services, 2004:68-87.
6. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 2002;324:886-91.
7. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72. [Erratum, JAMA 2003;290:197.]
8. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
10. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacologic intervention to prevent fractures. Arch Intern Med 2004;164:1108-12.
11. Physician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2003. (Accessed May 4, 2007, at www.nof.org/physguide/index.htm.)
12. Raisz LG. Screening for osteoporosis. N Engl J Med 2005;353:164-71.
13. Eddy DM, Johnston CC, Cummings SR, et al. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int 1998;8:Suppl:S1-S88.
14. De Laet C, Oden A, Johansson H, Johnell O, Jonsson B, Kanis JA. The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach. Osteoporos Int 2005;16:313-8.
15. Kanis JA, Black D, Cooper C, et al. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 2002;13:527-36.
16. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005;16:581-9.
17. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180-7.
18. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004;35:375-82.
19. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7.
20. Kaptoge S, Armbrecht G, Felsenberg D, et al. Whom to treat? The contribution of vertebral x-rays to risk-based algorithms for fracture prediction: results from the European Prospective Osteoporosis Study. Osteoporos Int 2006;17:1369-81.
21. Lewiecki EM, Laster AJ. Clinical applications of vertebral fracture assessment by dual-energy X-ray absorptiometry. J Clin Endocrinol Metab 2006;91:4215-22.
22. Seibel MJ. Biochemical markers of bone turnover. Part I: biochemistry and variability. Clin Biochem Rev 2005;26:97-122.
23. Miller PD, Baran DT, Bilezikian JP, et al. Practical clinical application of biochemical markers of bone turnover: consensus of an expert panel. J Clin Densitom 1999;2:323-42.
24. Hannon R, Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 2000;11:Suppl 6:S30-S44.
25. Jamal SA, Leiter RE, Bayoumi AM, Bauer DC, Cummings SR. Clinical utility of laboratory testing in women with osteoporosis. Osteoporos Int 2005;16:534-40.
26. Gaugris S, Heaney RP, Boonen S, Kurth H, Bentkover JD, Sen SS. Vitamin D inadequacy among post-menopausal women: a systematic review. QJM 2005;98:667-76.
27. Shea B, Wells G, Cranney A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 2002;23:552-9.
28. Papadimitropoulos E, Wells G, Shea B, et al. Meta-analyses of therapies for postmenopausal osreoporosis. VIII. Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:560-9.
29. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669-83. [Erratum, N Engl J Med 2006;354:11-2.]
30. Martyn-St James M, Carroll S. High-intensity resistance training and postmenopausal bone loss: a meta-analysis. Osteoporos Int 2006;17:1225-40.
31. Palombaro KM. Effects of walking-only interventions on bone mineral density at various skeletal sites: a meta-analysis. J Geriatr Phys Ther 2005;28:102-7.
32. Rosen CJ. Postmenopausal osteoporosis. N Engl J Med 2005;353:595-603.
33. Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23:508-16.
34. Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:517-23.
35. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:524-8.
36. Wells G, Tugwell P, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:529-39.
37. Kanis JA, Johnell O, Black DM, et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 2003;33:293-300.
38. Quandt SA, Thompson DE, Schneider DL, Nevitt MC, Black DM. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of -1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc 2005;80:343-9.
39. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
40. Cauley JA, Robbins J, Chen Z, et al. Effect of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729-38.
41. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001;12:989-95.
42. Schousboe JT, Nyman JA, Kane RL, Ensrud KE. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005;142:734-41.
43. Miller PD, Zapalowski C, Kulak CA, Bilezikian JP. Bone densitometry: the best way to detect osteoporosis and to monitor therapy. J Clin Endocrinol Metab 1999;84:1867-71.
44. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-41.
45. Blake GM, Chinn DJ, Steel SA, et al. A list of device-specific thresholds for the clinical interpretation of peripheral x-ray absorptiometry examinations. Osteoporos Int 2005;16:2149-56.
46. Melton LJ III. The prevalence of osteoporosis: gender and racial comparison. Calcif Tissue Int 2001;69:179-81.
47. Wilkins CH, Goldfeder JS. Osteoporosis screening is unjustifiably low in older African-American women. J Natl Med Assoc 2004;96:461-7.
48. Sinnott B, Kukreja SC, Barengolts EI. Utility of screening tools for the prediction of low bone mass in African American men. Osteoporos Int 2006;17:684-92.
49. Orces CH, Casas C, Lee S, Garcia-Cavazos R, White W. Determinants of osteoporosis prevention in low-income Mexican-American women. South Med J 2003;96:458-64.
50. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003;9:544-64. [Erratum, Endocr Pract 2004;10:90.]
51. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause 2006;13:340-67.
52. Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int 2006;17:1404-9.